reactogenicity

reactogenicity

(rē-ak-tō-je-nĭ-sĭ'tē),
State of being able to produce adverse reactions.
Farlex Partner Medical Dictionary © Farlex 2012

reactogenic

(rē-ak″tŏ-jen′ik) [ react(ion) + -genic]
Capable of producing a physiologic response, as a vaccine that elicits an antibody response.
reactogenicity (-jĕ-nis′ĭt-ē)
Medical Dictionary, © 2009 Farlex and Partners
Mentioned in ?
References in periodicals archive ?
This randomised, double-blind, placebo-controlled, phase 1/2a study will evaluate the safety, reactogenicity and immunogenicity of monovalent HPV16 and HPV18 Ad26-vectored vaccine components and an MVA-vectored HPV16/18 vaccine component (MVA-BN HPV) in 66 otherwise healthy women with persistent HPV16 or 18 infection of the cervix.
The trial's key objectives include evaluating the safety and tolerability, reactogenicity and humoral immunogenicity of mRNA-1653, and selecting the optimal dose and vaccination schedule for further clinical development.
Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
The candidate vaccine had an acceptable safety and reactogenicity profile.
A novel hepatitis B vaccine containing Advax[TM] a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.
Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report.
avium) were isolated from the diagnostic material and objects of the external environment of the steppe zone.Thesensitins from epizootic strains of mycobacteria were tested in terms of such criteria as sterility, safety, reactogenicity, lack of sensitizing properties, activity, and specificity.
"For example, one concern that arises is reactogenicity and inflammation.
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
Giving a lower dose to young children was planned to reduce reactogenicity and febrile convulsions observed with the whole virus vaccines that were in use in the 1970s.
The primary outcome measure was to compare the reactogenicity and immunogenicity between the monovalent and multivalent vaccines from the results of the available clinical trials.

Full browser ?